Document is current
Any future updates will be listed below
-
Authors
Moniot, Aurélie
Schneider, Christophe
Chardin, Laure
Yaniz-Galende, Elisa
Genestie, Catherine
Etiennot, Marion
Henry, Aubéri
Drelon, Coralie
Le Formal, Audrey
Langlois, Benoit
Venat, Laurence
Louvet, Christophe
Favier, Laure
Lortholary, Alain
Berton-Rigaud, Dominique
Dohollou, Nadine
Desauw, Christophe
Fabbro, Michel
Malaurie, Emmanuelle
Dubot, Coraline
Kurtz, Jean Emmanuel
Bonichon Lamichhane, Nathalie
Pujade-Lauraine, Éric
Jeanne, Albin
Leary, Alexandra
Dedieu, Stéphane
- License Information
-
More Information
Article History
Received: 13 May 2024
Accepted: 25 July 2024
First Online: 14 August 2024
Declarations
:
: All patients provided written informed consent authorizing the use of biological samples obtained during their diagnosis and treatment as part of the prospective academic research study (NCT01583322). The CHIVA protocol was approved by the French National Agency for Safety of Medicine and Health Products and the Committee on the Protection of Persons of Ile de France, ensuring participant rights. Confidentiality and privacy were rigorously maintained.
: AJ and SD serve as President and Chair of the Scientific and Clinical Advisory Board, respectively, and have equity interest in Apmonia Therapeutics (Reims, France) that licensed TAX2 technology for development. ALe declares an advisory role for Apmonia Therapeutics. ALo received honoraria from AstraZeneca, Clovis Oncology, MSD, Novartis, Roche, and Tesaro/GSK. CDu declares COI with GSK (punctual speaker), Amgen (punctual speaker), MSD (board), and Eisai (travel). JEK received honoraria from Dragonfly Therapeutics, travel accommodation from AstraZeneca, Eisai, Pharmamar, and GSK, is an advisor to AstraZeneca, Eisai, and GSK and a member of his immediate family is an employee of MSD. EPL declares financial relationship with Roche, GSK, Astra Zeneca (advisor) and with Agenus and Incyte (IDMC board member).
